Michael A. Vogelbaum
557 works · 30,456 citations · h-index 80
Top works
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
- A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
- Response assessment criteria for brain metastases: proposal from the RANO group
- Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): An American Society for Radiation Oncology evidence-based guideline
- Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials
- Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas
- Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline
- End Point Assessment in Gliomas: Novel Treatments Limit Usefulness of Classical Macdonald's Criteria
- Response Assessment in Neuro-Oncology Clinical Trials
- Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma
- RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults
- Application of Novel Response/Progression Measures for Surgically Delivered Therapies for Gliomas
- DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management
- Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma
- Federated learning enables big data for rare cancer boundary detection
- Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review
- Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma
- Prognostic validation of a new classification system for extent of resection in glioblastoma: A report of the RANO resect group
- Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group
- IL-13R(alpha)2, a decoy receptor for IL-13 acts as an inhibitor of IL-4-dependent signal transduction in glioblastoma cells.